Orphan Drugs Market Report by Drug Type, Disease Type, Phase, Top Selling Drugs, Distribution Channel, and Region 2024-2032

Description

List of Tables

The global orphan drugs market size reached US$ 214.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 541.3 Billion by 2032, exhibiting a growth rate (CAGR) of 10.5% during 2024-2032.

Orphan drugs refer to pharmaceutical products used for the diagnosis, prevention and treatment of rare medical disorders. These drugs are manufactured to meet a specific public health requirement and usually have a limited market as they are produced for a small group of patients. They are effective against numerous oncological, metabolic, hematologic, immunologic, infectious and neurological diseases. Medical ailments, such as lymphoma, leukemia, cystic fibrosis, glioma, pancreatic cancer, ovarian cancer, multiple myeloma and renal cell carcinoma, are often life-threatening, chronic, progressive, degenerative and disabling and require specific treatment alternatives that are effective for their particular symptoms.

Orphan Drugs Market Trends:

The increasing prevalence of cancer and other rare genetic disorders is one of the key factors driving the growth of the market. Pharmaceutical manufacturers are developing innovative orphan drugs to provide personalized therapy to patients. The market is also being driven by increasing awareness among the masses regarding the benefits of orphan drugs. The emergence of new pharmaceutical drug manufacturers and the implementation of favorable government policies to inhibit the spread of contagious diseases are also contributing to the market growth. Additionally, various product innovations, such as the development of biological orphan drugs, are acting as other growth-inducing factors. These drugs can treat diseases, such as cancer, and reverse the damage caused to the stem cells, which is facilitating their overall demand significantly. Other factors, including improvements in the healthcare infrastructure, along with extensive research and development (R&D) activities, are expected to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global orphan drugs market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on drug type, disease type, phase, top selling drugs and distribution channel.

Breakup by Drug Type:

Biological

Non-Biological

Breakup by Disease Type:

Oncology

Hematology

Neurology

Cardiovascular

Others

Breakup by Phase:

Phase I

Phase II

Phase III

Phase IV

Breakup by Top Selling Drugs:

Revlimid

Rituxan

Copaxone

Opdivo

Keytruda

Imbruvica

Avonex

Sensipar

Soliris

Others

Breakup by Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Stores

Others

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being AbbVie Inc., Alexion Pharmaceuticals Inc., Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG (Roche Holding AG), Jazz Pharmaceuticals Plc, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report

1. What was the size of the global orphan drugs market in 2023?
2. What is the expected growth rate of the global orphan drugs market during 2024-2032?
3. What are the key factors driving the global orphan drugs market?
4. What has been the impact of COVID-19 on the global orphan drugs market?
5. What is the breakup of the global orphan drugs market based on the drug type?
6. What is the breakup of the global orphan drugs market based on the disease type?
7. What is the breakup of the global orphan drugs market based on top selling drugs?
8. What is the breakup of the global orphan drugs market based on the distribution channel?
9. What are the key regions in the global orphan drugs market?
10. Who are the key players/companies in the global orphan drugs market?

Product Code: SR112024A2382

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Orphan Drugs Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Drug Type

6.1 Biological
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Non-Biological
- 6.2.1 Market Trends
- 6.2.2 Market Forecast

7 Market Breakup by Disease Type

7.1 Oncology
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Hematology
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Neurology
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
7.4 Cardiovascular
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
7.5 Others
- 7.5.1 Market Trends
- 7.5.2 Market Forecast

8 Market Breakup by Phase

8.1 Phase I
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Phase II
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Phase III
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
8.4 Phase IV
- 8.4.1 Market Trends
- 8.4.2 Market Forecast

9 Market Breakup by Top Selling Drugs

9.1 Revlimid
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
9.2 Rituxan
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
9.3 Copaxone
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
9.4 Opdivo
- 9.4.1 Market Trends
- 9.4.2 Market Forecast
9.5 Keytruda
- 9.5.1 Market Trends
- 9.5.2 Market Forecast
9.6 Imbruvica
- 9.6.1 Market Trends
- 9.6.2 Market Forecast
9.7 Avonex
- 9.7.1 Market Trends
- 9.7.2 Market Forecast
9.8 Sensipar
- 9.8.1 Market Trends
- 9.8.2 Market Forecast
9.9 Soliris
- 9.9.1 Market Trends
- 9.9.2 Market Forecast
9.10 Others
- 9.10.1 Market Trends
- 9.10.2 Market Forecast

10 Market Breakup by Distribution Channel

10.1 Hospital Pharmacies
- 10.1.1 Market Trends
- 10.1.2 Market Forecast
10.2 Retail Pharmacies
- 10.2.1 Market Trends
- 10.2.2 Market Forecast
10.3 Online Stores
- 10.3.1 Market Trends
- 10.3.2 Market Forecast
10.4 Others
- 10.4.1 Market Trends
- 10.4.2 Market Forecast

11 Market Breakup by Region

11.1 North America
- 11.1.1 United States
  - 11.1.1.1 Market Trends
  - 11.1.1.2 Market Forecast
- 11.1.2 Canada
  - 11.1.2.1 Market Trends
  - 11.1.2.2 Market Forecast
11.2 Asia Pacific
- 11.2.1 China
  - 11.2.1.1 Market Trends
  - 11.2.1.2 Market Forecast
- 11.2.2 Japan
  - 11.2.2.1 Market Trends
  - 11.2.2.2 Market Forecast
- 11.2.3 India
  - 11.2.3.1 Market Trends
  - 11.2.3.2 Market Forecast
- 11.2.4 South Korea
  - 11.2.4.1 Market Trends
  - 11.2.4.2 Market Forecast
- 11.2.5 Australia
  - 11.2.5.1 Market Trends
  - 11.2.5.2 Market Forecast
- 11.2.6 Indonesia
  - 11.2.6.1 Market Trends
  - 11.2.6.2 Market Forecast
- 11.2.7 Others
  - 11.2.7.1 Market Trends
  - 11.2.7.2 Market Forecast
11.3 Europe
- 11.3.1 Germany
  - 11.3.1.1 Market Trends
  - 11.3.1.2 Market Forecast
- 11.3.2 France
  - 11.3.2.1 Market Trends
  - 11.3.2.2 Market Forecast
- 11.3.3 United Kingdom
  - 11.3.3.1 Market Trends
  - 11.3.3.2 Market Forecast
- 11.3.4 Italy
  - 11.3.4.1 Market Trends
  - 11.3.4.2 Market Forecast
- 11.3.5 Spain
  - 11.3.5.1 Market Trends
  - 11.3.5.2 Market Forecast
- 11.3.6 Russia
  - 11.3.6.1 Market Trends
  - 11.3.6.2 Market Forecast
- 11.3.7 Others
  - 11.3.7.1 Market Trends
  - 11.3.7.2 Market Forecast
11.4 Latin America
- 11.4.1 Brazil
  - 11.4.1.1 Market Trends
  - 11.4.1.2 Market Forecast
- 11.4.2 Mexico
  - 11.4.2.1 Market Trends
  - 11.4.2.2 Market Forecast
- 11.4.3 Others
  - 11.4.3.1 Market Trends
  - 11.4.3.2 Market Forecast
11.5 Middle East and Africa
- 11.5.1 Market Trends
- 11.5.2 Market Breakup by Country
- 11.5.3 Market Forecast

12 SWOT Analysis

12.1 Overview
12.2 Strengths
12.3 Weaknesses
12.4 Opportunities
12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

14.1 Overview
14.2 Bargaining Power of Buyers
14.3 Bargaining Power of Suppliers
14.4 Degree of Competition
14.5 Threat of New Entrants
14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

16.1 Market Structure
16.2 Key Players
16.3 Profiles of Key Players
- 16.3.1 AbbVie Inc.
  - 16.3.1.1 Company Overview
  - 16.3.1.2 Product Portfolio
  - 16.3.1.3 Financials
  - 16.3.1.4 SWOT Analysis
- 16.3.2 Alexion Pharmaceuticals Inc.
  - 16.3.2.1 Company Overview
  - 16.3.2.2 Product Portfolio
  - 16.3.2.3 Financials
  - 16.3.2.4 SWOT Analysis
- 16.3.3 Amgen Inc.
  - 16.3.3.1 Company Overview
  - 16.3.3.2 Product Portfolio
  - 16.3.3.3 Financials
  - 16.3.3.4 SWOT Analysis
- 16.3.4 Biogen Inc.
  - 16.3.4.1 Company Overview
  - 16.3.4.2 Product Portfolio
  - 16.3.4.3 Financials
  - 16.3.4.4 SWOT Analysis
- 16.3.5 Bristol Myers Squibb Company
  - 16.3.5.1 Company Overview
  - 16.3.5.2 Product Portfolio
  - 16.3.5.3 Financials
  - 16.3.5.4 SWOT Analysis
- 16.3.6 F. Hoffmann-La Roche AG (Roche Holding AG)
  - 16.3.6.1 Company Overview
  - 16.3.6.2 Product Portfolio
  - 16.3.6.3 SWOT Analysis
- 16.3.7 Jazz Pharmaceuticals Plc
  - 16.3.7.1 Company Overview
  - 16.3.7.2 Product Portfolio
  - 16.3.7.3 Financials
  - 16.3.7.4 SWOT Analysis
- 16.3.8 Johnson & Johnson
  - 16.3.8.1 Company Overview
  - 16.3.8.2 Product Portfolio
  - 16.3.8.3 Financials
  - 16.3.8.4 SWOT Analysis
- 16.3.9 Merck & Co. Inc.
  - 16.3.9.1 Company Overview
  - 16.3.9.2 Product Portfolio
  - 16.3.9.3 Financials
  - 16.3.9.4 SWOT Analysis
- 16.3.10 Novartis AG
  - 16.3.10.1 Company Overview
  - 16.3.10.2 Product Portfolio
  - 16.3.10.3 Financials
  - 16.3.10.4 SWOT Analysis
- 16.3.11 Pfizer Inc.
  - 16.3.11.1 Company Overview
  - 16.3.11.2 Product Portfolio
  - 16.3.11.3 Financials
  - 16.3.11.4 SWOT Analysis
- 16.3.12 Sanofi S.A.
  - 16.3.12.1 Company Overview
  - 16.3.12.2 Product Portfolio
  - 16.3.12.3 Financials
  - 16.3.12.4 SWOT Analysis
- 16.3.13 Takeda Pharmaceutical Company Limited
  - 16.3.13.1 Company Overview
  - 16.3.13.2 Product Portfolio
  - 16.3.13.3 Financials
  - 16.3.13.4 SWOT Analysis
- 16.3.14 Teva Pharmaceutical Industries Ltd
  - 16.3.14.1 Company Overview
  - 16.3.14.2 Product Portfolio
  - 16.3.14.3 Financials
  - 16.3.14.4 SWOT Analysis

Product Code: SR112024A2382

List of Figures

Figure 1: Global: Orphan Drugs Market: Major Drivers and Challenges
Figure 2: Global: Orphan Drugs Market: Sales Value (in Billion US$), 2018-2023
Figure 3: Global: Orphan Drugs Market: Breakup by Drug Type (in %), 2023
Figure 4: Global: Orphan Drugs Market: Breakup by Disease Type (in %), 2023
Figure 5: Global: Orphan Drugs Market: Breakup by Phase (in %), 2023
Figure 6: Global: Orphan Drugs Market: Breakup by Top Selling Drugs (in %), 2023
Figure 7: Global: Orphan Drugs Market: Breakup by Distribution Channel (in %), 2023
Figure 8: Global: Orphan Drugs Market: Breakup by Region (in %), 2023
Figure 9: Global: Orphan Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
Figure 10: Global: Orphan Drugs (Biological) Market: Sales Value (in Million US$), 2018 & 2023
Figure 11: Global: Orphan Drugs (Biological) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 12: Global: Orphan Drugs (Non-Biological) Market: Sales Value (in Million US$), 2018 & 2023
Figure 13: Global: Orphan Drugs (Non-Biological) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 14: Global: Orphan Drugs (Oncology) Market: Sales Value (in Million US$), 2018 & 2023
Figure 15: Global: Orphan Drugs (Oncology) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 16: Global: Orphan Drugs (Hematology) Market: Sales Value (in Million US$), 2018 & 2023
Figure 17: Global: Orphan Drugs (Hematology) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 18: Global: Orphan Drugs (Neurology) Market: Sales Value (in Million US$), 2018 & 2023
Figure 19: Global: Orphan Drugs (Neurology) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 20: Global: Orphan Drugs (Cardiovascular) Market: Sales Value (in Million US$), 2018 & 2023
Figure 21: Global: Orphan Drugs (Cardiovascular) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 22: Global: Orphan Drugs (Other Disease Types) Market: Sales Value (in Million US$), 2018 & 2023
Figure 23: Global: Orphan Drugs (Other Disease Types) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 24: Global: Orphan Drugs (Phase I) Market: Sales Value (in Million US$), 2018 & 2023
Figure 25: Global: Orphan Drugs (Phase I) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 26: Global: Orphan Drugs (Phase II) Market: Sales Value (in Million US$), 2018 & 2023
Figure 27: Global: Orphan Drugs (Phase II) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 28: Global: Orphan Drugs (Phase III) Market: Sales Value (in Million US$), 2018 & 2023
Figure 29: Global: Orphan Drugs (Phase III) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 30: Global: Orphan Drugs (Phase IV) Market: Sales Value (in Million US$), 2018 & 2023
Figure 31: Global: Orphan Drugs (Phase IV) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 32: Global: Orphan Drugs (Revlimid) Market: Sales Value (in Million US$), 2018 & 2023
Figure 33: Global: Orphan Drugs (Revlimid) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 34: Global: Orphan Drugs (Rituxan) Market: Sales Value (in Million US$), 2018 & 2023
Figure 35: Global: Orphan Drugs (Rituxan) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 36: Global: Orphan Drugs (Copaxone) Market: Sales Value (in Million US$), 2018 & 2023
Figure 37: Global: Orphan Drugs (Copaxone) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 38: Global: Orphan Drugs (Opdivo) Market: Sales Value (in Million US$), 2018 & 2023
Figure 39: Global: Orphan Drugs (Opdivo) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 40: Global: Orphan Drugs (Keytruda) Market: Sales Value (in Million US$), 2018 & 2023
Figure 41: Global: Orphan Drugs (Keytruda) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 42: Global: Orphan Drugs (Imbruvica) Market: Sales Value (in Million US$), 2018 & 2023
Figure 43: Global: Orphan Drugs (Imbruvica) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 44: Global: Orphan Drugs (Avonex) Market: Sales Value (in Million US$), 2018 & 2023
Figure 45: Global: Orphan Drugs (Avonex) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 46: Global: Orphan Drugs (Sensipar) Market: Sales Value (in Million US$), 2018 & 2023
Figure 47: Global: Orphan Drugs (Sensipar) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 48: Global: Orphan Drugs (Soliris) Market: Sales Value (in Million US$), 2018 & 2023
Figure 49: Global: Orphan Drugs (Soliris) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 50: Global: Orphan Drugs (Other Drugs) Market: Sales Value (in Million US$), 2018 & 2023
Figure 51: Global: Orphan Drugs (Other Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 52: Global: Orphan Drugs (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
Figure 53: Global: Orphan Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 54: Global: Orphan Drugs (Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
Figure 55: Global: Orphan Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 56: Global: Orphan Drugs (Online Stores) Market: Sales Value (in Million US$), 2018 & 2023
Figure 57: Global: Orphan Drugs (Online Stores) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 58: Global: Orphan Drugs (Other Distribution Channels) Market: Sales Value (in Million US$), 2018 & 2023
Figure 59: Global: Orphan Drugs (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 60: North America: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 61: North America: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 62: United States: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 63: United States: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 64: Canada: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 65: Canada: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 66: Asia Pacific: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 67: Asia Pacific: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 68: China: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 69: China: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 70: Japan: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 71: Japan: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 72: India: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 73: India: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 74: South Korea: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 75: South Korea: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 76: Australia: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 77: Australia: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 78: Indonesia: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 79: Indonesia: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 80: Others: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 81: Others: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 82: Europe: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 83: Europe: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 84: Germany: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 85: Germany: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 86: France: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 87: France: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 88: United Kingdom: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 89: United Kingdom: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 90: Italy: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 91: Italy: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 92: Spain: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 93: Spain: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 94: Russia: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 95: Russia: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 96: Others: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 97: Others: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 98: Latin America: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 99: Latin America: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 100: Brazil: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 101: Brazil: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 102: Mexico: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 103: Mexico: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 104: Others: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 105: Others: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 106: Middle East and Africa: Orphan Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 107: Middle East and Africa: Orphan Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 108: Global: Orphan Drugs Industry: SWOT Analysis
Figure 109: Global: Orphan Drugs Industry: Value Chain Analysis
Figure 110: Global: Orphan Drugs Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Orphan Drugs Market: Key Industry Highlights, 2023 and 2032
Table 2: Global: Orphan Drugs Market Forecast: Breakup by Drug Type (in Million US$), 2024-2032
Table 3: Global: Orphan Drugs Market Forecast: Breakup by Disease Type (in Million US$), 2024-2032
Table 4: Global: Orphan Drugs Market Forecast: Breakup by Phase (in Million US$), 2024-2032
Table 5: Global: Orphan Drugs Market Forecast: Breakup by Top Selling Drugs (in Million US$), 2024-2032
Table 6: Global: Orphan Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
Table 7: Global: Orphan Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
Table 8: Global: Orphan Drugs Market Structure
Table 9: Global: Orphan Drugs Market: Key Players

Orphan Drugs Market Report by Drug Type, Disease Type, Phase, Top Selling Drugs, Distribution Channel, and Region 2024-2032

Description

Table of Contents

List of Tables

Orphan Drugs Market Trends:

Key Market Segmentation:

Breakup by Drug Type:

Breakup by Disease Type:

Breakup by Phase:

Breakup by Top Selling Drugs:

Breakup by Distribution Channel:

Breakup by Region:

Competitive Landscape:

Key Questions Answered in This Report

Table of Contents

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

5 Global Orphan Drugs Market

6 Market Breakup by Drug Type

7 Market Breakup by Disease Type

8 Market Breakup by Phase

9 Market Breakup by Top Selling Drugs

10 Market Breakup by Distribution Channel

11 Market Breakup by Region

12 SWOT Analysis

13 Value Chain Analysis

14 Porters Five Forces Analysis

15 Price Analysis

16 Competitive Landscape

List of Figures

List of Tables